التفاصيل البيبلوغرافية
| العنوان: |
Prevalence of anti-TNF contraindications in Crohn's disease: A cross-sectional survey from the GETAID. |
| المؤلفون: |
Amiot, Aurélien, Seksik, Philippe, Reimund, Jean-Marie, Nachury, Maria, Altwegg, Romain, Bourreille, Arnaud, Viennot, Stephanie, Fumery, Mathurin, Roblin, Xavier, Serrero, Melanie, Allez, Matthieu, Painchart, Claire, Chanteloup, Elise, Vuitton, Lucine, Fotsing, Ginette, Buisson, Anthony, Coulibaly, Baya, Nancey, Stephane, Gilletta, Cyrielle, Plastaras, Laurianne, Abitbol, Vered, Guillo, Lucas, Simon, Marion, Nahon, Stephane, Laharie, David, Peyrin-Biroulet, Laurent, Bouguen, Guillaume |
| المساهمون: |
Université de Lille, Inserm, CHU Lille, Hôpital Henri Mondor, CHU Saint-Antoine AP-HP, Interface de Recherche Fondamentale et Appliquée en Cancérologie IRFAC - Inserm U1113, Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286, Centre Hospitalier Régional Universitaire Montpellier CHRU Montpellier, Institut des Maladies de l'Appareil Digestif, CHU Caen, Périnatalité et Risques Toxiques - UMR INERIS_I 1 PERITOX, Centre Hospitalier Universitaire de Saint-Etienne CHU Saint-Etienne CHU ST-E, Aix Marseille Université AMU, Hopital Saint-Louis AP-HP AP-HP, Centre hospitalier Valenciennes, Nord, Centre hospitalier Saint-Joseph Paris, Centre Hospitalier Régional Universitaire de Besançon CHRU Besançon, Centre hospitalier universitaire de Poitiers = Poitiers University Hospital CHU de Poitiers, CHU Clermont-Ferrand, Centre Hospitalier Henri Duffaut (Avignon), Hospices Civils de Lyon HCL, Centre Hospitalier Universitaire de Toulouse CHU Toulouse, CH Colmar, Hôpital Cochin AP-HP, Institut Mutualiste de Montsouris IMM, Groupe Hospitalier Intercommunal Le Raincy-Montfermeil, CHU Bordeaux, Nutrition-Génétique et Exposition aux Risques Environnementaux NGERE, Nutrition, Métabolismes et Cancer NuMeCan |
| سنة النشر: |
2024 |
| المجموعة: |
LillOA (Lille Open Archive - Université de Lille) |
| مصطلحات موضوعية: |
Anti-TNF, Contraindication, Crohn?s disease, Inflammatory bowel disease |
| الوصف: |
Background The exact rate of contraindications to anti-TNF therapy and physician perspectives on treatment choices facing to anti-TNF contraindication, are poorly reported. Methods A two-week cross-sectional study was conducted in 31 centres. Physicians completed a questionnaire for a total of 1,314 consecutive outpatients with Crohn's disease, assessing each patient's potential contraindications to anti-TNF therapy, the choice of alternative therapy to anti-TNFs, and their preference in an unrestricted reimbursement setting. Results Among the 1,293 responses to the first item, 148 (11.5%) reported 32 absolute contraindications (2.5%) and 116 relative contraindications (9.0%) to anti-TNF therapy. When asked about their preference of alternative therapies in those cases with contraindications to anti-TNF, physicians chose ustekinumab and vedolizumab, 75.6% and 23.9%, respectively. In multivariable analysis, the choice of vedolizumab was the preferred choice for patients aged > 60 years with the L2 phenotype and the absence of perianal lesions. In a hypothetical setting of unrestricted reimbursement, anti-TNFs remained physicians’ preferred first-line biological therapy choice for 78.2%. Conclusion Anti-TNF contraindications occurred in up to 11.5% of patients with Crohn's disease. Physicians’ choices for alternative therapy to anti-TNF relied on ustekinumab in 75.6% and vedolizumab in 23.9% of these cases. This choice was driven mainly by phenotypical criteria and age. ; 54 |
| نوع الوثيقة: |
article in journal/newspaper |
| وصف الملف: |
application/octet-stream |
| اللغة: |
English |
| Relation: |
Digestive and Liver Disease; Dig Liver Dis; http://hdl.handle.net/20.500.12210/100817 |
| الاتاحة: |
https://hdl.handle.net/20.500.12210/100817 |
| Rights: |
info:eu-repo/semantics/openAccess |
| رقم الانضمام: |
edsbas.2D38DF3D |
| قاعدة البيانات: |
BASE |